A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

Document Details

Document Type
Pub Defense Publication
Publication Date
May 01, 2020
Source ID
10.1016/j.annonc.2020.01.074

Entities

People

  • A. Sharp
  • D. Bianchini
  • D. Nava Rodrigues
  • E. Hall
  • F.i. Raynaud
  • H. Tovey
  • I. Figueiredo
  • J. Mateo
  • J. Welti
  • J.s. De Bono
  • Jiangyi Luo
  • K.e. Swales
  • L. Leonard
  • M. Crespo
  • M. Lambros
  • M.p. Kolinsky
  • N. Mehra
  • N. Porta
  • N. Tunariu
  • P. Rescigno
  • Penny Flohr
  • R. Riisnaes
  • R. Ruddle
  • R. Slade
  • S. Carreira
  • S. Miranda
  • S. Plymate
  • U. Banerji
  • V. Michalarea
  • Z. Zafeiriou

Organizations

  • Astellas Pharma
  • Cancer Research UK
  • European Society for Medical Oncology
  • Movember Foundation
  • National Institute for Health and Care Research
  • Prostate Cancer Foundation
  • Prostate Cancer UK
  • United States Department of Defense